<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> for 2 h by occlusion of the right middle cerebral artery provoked severe <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> in the rat brain after 24 h </plain></SENT>
<SENT sid="1" pm="."><plain>Intraperitoneal administration of histidine, a precursor of <z:chebi fb="11" ids="18295">histamine</z:chebi>, immediately and 6 h after reperfusion, alleviated <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> size in the histidine (200 mg/kg, 500 mg/kg, and 1000 mg/kg, each time) groups was 71%, 39%, and 7% of that in the control group, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>Although intracerebroventricular administration of <z:chebi fb="0" ids="6762">mepyramine</z:chebi> (3 nmol), an H1 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, did not affect the morphologic outcome in histidine-treated rats, <z:chebi fb="10" ids="8776">ranitidine</z:chebi> (30 nmol), an H2 <z:chebi fb="68" ids="48706">antagonist</z:chebi>, completely abolished the alleviation caused by histidine </plain></SENT>
<SENT sid="4" pm="."><plain>These findings indicate that postischemic administration of histidine prevents development of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> by stimulating central <z:chebi fb="11" ids="18295">histamine</z:chebi> H2 receptors </plain></SENT>
</text></document>